Signal
Three years after its OrbiMed-backed series A in 2023, Sidewinder Therapeutics is adding to its nest egg courtesy of a clutch of new investors. The San Diego...
Evidence first: scan the strongest sources, then decide whether to go deeper.
Published 2026-04-08 11:08 UTCUpdated 2026-04-08 17:05 UTC
rss
biopharma_dive
Source links open
Source links and full evidence are open here. Archive history, compare-over-time, alerts, exports, API, integrations, and workflow are paid.
No card needed for the free brief.
Evidence trail (top sources)
top sources (2 domains)domains are deduped. counts indicate coverage, not truth.2 top sources shown
limited source diversity in top sources
Overview
Backed by OrbiMed, Novartis’ venture arm and many other investors, the biotech is among those working on newer technology that could broaden the reach of antibody-drug conjugates.
Score total
0.99
Momentum 24h
2
Posts
2
Origins
2
Source types
1
Duplicate ratio
0%
All evidence
All evidence
Sidewinder secures $137M to advance ‘precision’ ADCs
BioPharma Dive · biopharmadive.com · 2026-04-08 17:05 UTC
Three years after its OrbiMed-backed series A in 2023, Sidewinder Therapeutics is adding to its nest egg courtesy of a clutch of new investors. The San Diego startup has sunk it...
Fierce Biotech · fiercebiotech.com · 2026-04-08 11:08 UTC
Show filters & breakdown
Posts loaded: 0Publishers: 2Origin domains: 2Duplicates: -
Showing 2 / 0
Top publishers (this list)
- BioPharma Dive (1)
- Fierce Biotech (1)
Top origin domains (this list)
- biopharmadive.com (1)
- fiercebiotech.com (1)